Correvio Pharma (CORV) Misses Q3 EPS by 6c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Correvio Reports Third Quarter 2019 Financial Results
November 14, 2019 7:00 AM ESTNASDAQ: CORVÂ TSX: CORV
FDA Accepts Brinavess New Drug Application
Advisory Committee Date Set for December 10, 2019
PDUFA Date Set for December 24, 2019
Management to Host Conference Call and Webcast Today, November 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific)
VANCOUVER, Nov. 14, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its third quarter... More
